Article
HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.
Tissue antigens - 1 Sept 2011
Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, Peretz T
Abstract excerpt
This work presents survival data of 42 melanoma patients at high risk for disease recurrence who received an allogeneic melanoma vaccine composed of three cell lines, each matching at least one allele of the recipient's human leukocyte antigen (HLA)-A and -B loci. The 5-year overall survival (OS) rate and disease-free survival (DFS) compared favorably with the standard interferon-α regimen. Interestingly,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.